Resolving the Problems on Look-Alike Sound-Alike Drugs at the System Level
Article Sidebar
Main Article Content
Abstract
Objective: To propose the suggestions for resolving the problems on look-alike sound-alike (LASA) drugs at the system level. Method: The researcher reviewed laws and regulations regarding LASA drugs mainly under the Bureau of Drug Control, Food and Drug Administration. The study also reviewed the measures for curbing this problem drugs in Thailand and abroad including the suggestions from the World Health Organization. The researcher prepared recommendations at the system level and presented them to 14 experts whose work involving drug registration or having publications on LASA drugs with more than 10 years of working experiences. Results: There were no current Thai laws and regulations directly addressing LASA drugs. However the Drug Act B.E.2510 mentioned "registered drugs potentially unsafe for users" and "drugs with names that potentially mislead" which may LASA drugs. At present, systematic address of the problem was not found. In the other countries, the measures for addressing the problem were different depending on the context within the countries with some measures applicable to Thailand. Conclusion: the study provided suggestions for regulatory agencies responsible for the problem on LASA drugs on urgent, intermediate and long term measures.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
2. Department of Health Service Support. National patient safety goal. Nonthaburi: Ministry of Public Health: 2007-2008.
3. Chumchit C. Development of medication safety management system for Look-Alike Sound-Alike drugs in public hospital [dissertation]. Nakorn Pratom: Silpakorn University; 2013.
4. Academic Centers for Drug System Surveillance and Development. Drug system situation report [online]. 2009 [cited Oct 7,2016]. Available from: www.thaidrugwatch.org/download/otherprint/otherprint01.pdf.
5. Drug Act, B.E. 2510 (1967). Royal Gazette No. 84, Part 101 special (Oct 20,1967).
6. Drug Act, Amendment (No.3), B.E.2522 (1979). Royal Gazette No. 96, Part 79 special (May 13, 1979).
7. Drug Act, Amendment (No.5), B.E.2530 (1987). Royal Gazette No. 104, Part 278 special (Dec 31, 1987).
8. Ministerial regulations on drug registration B.E.2555 (2012).Royal Gazette No.129, Part102A (Oct 25, 2012).
9. Public Health Ministerial Declaration in 2015 on the electronic application for drug registration. Royal Gazette No. 132, Part 321D special (Dec 3, 2015).
10. Center for Information Technology and Communica- tions in the Supreme Court. Judgment of the supreme court No. 7833/2538 [online]. 1995 [cited Mar 29, 2017]. Available from: deka.supremecourt. or.th/search
11. Center for Information Technology and Communica- tions in the Supreme Court. Judgment of the supreme court No. 1506/2538. [online]. 1995 [cited Mar 29, 2017]. Available from: deka.supremecourt. or. th/search
12. Trademark Act, B.E. 2534. Royal Gazette No. 108, Part 199 special (Nov 15, 1991).
13. U.S.Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: best practices in developing proprietary names for drugs. [online]. 2014 [cited Nov 17, 2016]. Available from: www.fda.gov/down loads/ drugs/guidances/ucm398997.pdf.
14. Hong Kong Authority. Sharing of good practices to manage LASA drugs. [online]. 2011 [cited Nov 17,2016]. Available from: www.ha.org.hk/haho/ho/ pspa_mirp/medsafetybulletin_vol_2.pdf.
15. Pharmaceutical Services Division, Ministry Of Health Malaysia. Guide on Handling Look Alike Sound Alike Medications. [online]. 2012 [cited Nov 18,2016]. Available from: www.pharmacy.gov.my/v2 /sites/default/files/document-upload/guide-handling-lasa.pdf.
16. Food and Drug Administration, Center for Drug Evaluation and Research. POCA User Guide-version 4.0. [online]. 2016 [cited Nov 20,2016]. Available from: www.google.co.th/?gws_rd=cr&ei= 2OUEVtvPFZHnuQSe-ZjwAw#q=POCA+User+ Guide-version+4.0.
17. Med ERRS. ERR on the side of safety. [online]. 1997 [cited Nov 20, 2016]. Available from: www.med -errs.com/contents/WhatWeDo.aspx.
18. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, Science Medicines Health. Guideline on the acceptability of names for human medicinal products processed through the centralised procedure [online]. 2014 [cited Nov 17,2016]. Available from: www.ema.eu ropa.eu/docs/en_GB/document_library/Regulatory_ and_procedural_guideline/2014/06/WC500167844.pdf.
19. U.S. Food and Drug Administration. Name Differentiation Project. [online]. 2001 [cited Nov 17, 2016]. Available from: www.fda.gov/Drugs/DrugSafe ty/MedicationErrors/ucm164587.htm.